Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Moss

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Vaccine|June 2, 1998
Safety and immunogenicity of REMUNE in HIV-infected Thai subjectsA Limsuwan, V Churdboonchart, R B Moss, et al.
Ear, Nose, & Throat Journal|February 1, 1997
Microsporidium-associated sinusitisR B Moss, L M Beaudet, B M Wenig, et al.
The Journal of Allergy and Clinical Immunology|February 1, 1984
Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitisC Ortolani, E Pastorello, R B Moss, et al.
Case Reports in Medicine|March 5, 2016
DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical VentilationB Dhakal, A D'Souza, M Pasquini, et al.
AIDS Research and Human Retroviruses|July 22, 1998
A primer on HIV type 1-specific immune function and REMUNER B Moss, W K Giermakowska, J R Savary, et al.
AIDS (London, England)|September 4, 1998
Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in ThailandV Churdboonchart, R B Moss, W Sirawaraporn, et al.
Clinical and Diagnostic Laboratory Immunology|May 30, 1998
In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune)R B Moss, M R Wallace, P Lanza, et al.
Vaccine|May 1, 1998
Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccinationP Lanza, R B Moss, W Giermakowska, et al.
Clinical and Experimental Immunology|May 3, 2002
Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccinationR B Moss, M R Wallace, R T Steigbigel, et al.
Viral Immunology|January 1, 1997
Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjectsR B Moss, W Giermakowska, P Lanza, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Vaccine|June 2, 1998
Safety and immunogenicity of REMUNE in HIV-infected Thai subjectsA Limsuwan, V Churdboonchart, R B Moss, et al.
Ear, Nose, & Throat Journal|February 1, 1997
Microsporidium-associated sinusitisR B Moss, L M Beaudet, B M Wenig, et al.
The Journal of Allergy and Clinical Immunology|February 1, 1984
Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitisC Ortolani, E Pastorello, R B Moss, et al.
Case Reports in Medicine|March 5, 2016
DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical VentilationB Dhakal, A D'Souza, M Pasquini, et al.
AIDS Research and Human Retroviruses|July 22, 1998
A primer on HIV type 1-specific immune function and REMUNER B Moss, W K Giermakowska, J R Savary, et al.
AIDS (London, England)|September 4, 1998
Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in ThailandV Churdboonchart, R B Moss, W Sirawaraporn, et al.
Clinical and Diagnostic Laboratory Immunology|May 30, 1998
In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune)R B Moss, M R Wallace, P Lanza, et al.
Vaccine|May 1, 1998
Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccinationP Lanza, R B Moss, W Giermakowska, et al.
Clinical and Experimental Immunology|May 3, 2002
Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccinationR B Moss, M R Wallace, R T Steigbigel, et al.
Viral Immunology|January 1, 1997
Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjectsR B Moss, W Giermakowska, P Lanza, et al.
Pageof 12